A randomized, double-blind, placebo-controlled, parallel group, Phase 3 study, followed by an open-label extension to evaluate the efficacy of oral belumosudil in adult participants with chronic ling allograft dysfunction (CLAD) following bilateral lung transplantation.

This study will be enrolling subjects who have Stage 1 or 2 chronic lung allograft dysfunction (CLAD) or “chronic lung rejection” after bilateral lung transplantation. This study is to evaluate an investigational drug, belumosudil (also known as SAR445761 or Rezurock) for the treatment of CLAD. “Investigational” means SAR445761 is not approved by the U.S. Food and Drug Administration (FDA) or any other regulatory body for use with chronic lung rejection. However, it is FDA approved for use in some instances of chronic graft versus host disease (cGVHD).